A man in his mid-30s presented with 1 week of painful, progressive, and confluent tongue and chin ulcerations. Swabs of the lesions were detected positive for monkeypox (mpox) DNA by polymerase chain reaction. During hospitalization, he received a diagnosis of human immunodeficiency virus-1. Due to severe oral pain, the patient was treated with intravenous tecovirimat 200 mg every 12 h for 4 days with remarkable improvement in lingual lesions. He completed a total 14-day course with oral tecovirimat. Our patient's clinical progress contributes to the data available for the potential efficacy of intravenous tecovirimat for mpox infection in humans.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jmv.29078 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fatal borealpox in an immunosuppressed patient treated with antivirals and vaccinia immunoglobulin - Alaska, 2023.
Clin Infect Dis
November 2024
Section of Epidemiology, Alaska Division of Public Health, Anchorage, Alaska, USA.
Background: Borealpox virus (BRPV, formerly known as Alaskapox virus) is a zoonotic member of the Orthopoxvirus genus first identified in a person in 2015. In the six patients with infection previously observed BRPV involved mild, self-limiting illness. We report the first fatal BRPV infection in an immunosuppressed patient.
View Article and Find Full Text PDFUpdate on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes.
Drugs
January 2025
Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD, 21201, USA.
Mpox, caused by the monkeypox virus (MPXV), is categorized into two primary clades: Clade I and Clade II, with notable outbreaks linked to Clade IIb. Historically endemic in Africa, recent years have seen significant global spread. The World Health Organization (WHO) declared mpox a Public Health Emergency of International Concern in August 2024, highlighting the emergence of Clade Ib outside Africa and the broadening demographic impact of the outbreak.
View Article and Find Full Text PDFWe report a case of persistent disseminated mpox evolving over >6 months in an HIV/hepatitis B virus co-infected patient in France who had <200 CD4+ cells/mm, pulmonary and hepatic necrotic lesions, persistent viremia, and nasopharyngeal excretion. Clinical outcome was favorable after 90 days of tecovirimat treatment and administration of human vaccinia immunoglobulins.
View Article and Find Full Text PDFMpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies: A Review.
JAMA
November 2024
Division of Infectious Diseases, Columbia University Irving Medical Center, New York, New York.
Article Synopsis
- * Mpox is mainly transmitted through direct skin-to-skin contact, with a significant association with sexual activity among gay and bisexual men; symptoms typically include fever, swollen lymph nodes, and a progression of skin lesions.
- * Although clade IIb MPXV usually leads to a self-limited illness, severe cases can occur in immunocompromised individuals; supportive care is emphasized, and antiviral treatments are in various access programs or trials,
Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022-2023.
NEJM Evid
October 2024
Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta.
Background: During the ongoing outbreak of clade II (MPXV), many U.S. patients were prescribed tecovirimat, an antiviral drug that was made available under an expanded access Investigational New Drug (EA-IND) program.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!